Acute Kidney Injury — PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy
Citation(s)
Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med. 2008 Feb;36(2):610-7. doi: 10.1097/01.CCM.0B013E3181611F552. Review.
Bell M, Liljestam E, Granath F, Fryckstedt J, Ekbom A, Martling CR Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. Nephrol Dial Transplant. 2005 Feb;20(2):354-60. Epub 2004 Dec 14.
Bell M; SWING, Granath F, Schön S, Ekbom A, Martling CR Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. Intensive Care Med. 2007 May;33(5):773-80. Epub 2007 Mar 16.
Bouman CS, Forni LG Initiation of renal replacement therapy: is timing everything? Crit Care. 2010;14(1):107. doi: 10.1186/cc8188. Epub 2010 Feb 10.
Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002 Oct;30(10):2205-11.
Davenport A Clinical guidelines for the protection of kidney function and prevention of acute kidney injury in the intensive care unit: common sense rather than magic bullets? Intensive Care Med. 2010 Mar;36(3):379-80. doi: 10.1007/s00134-009-1683-1.
Hoste EA, Schurgers M Epidemiology of acute kidney injury: how big is the problem? Crit Care Med. 2008 Apr;36(4 Suppl):S146-51. doi: 10.1097/CCM.0b013e318168c590. Review.
Hoste EAJ, J A. K, group TAKI-EPIs: The epidemiology of acute kidney injury - Preliminary results of the multicenter international AKI-EPI study. Intensive Care Med 2011, 37: S207
Legrand M, Darmon M, Joannidis M, Payen D Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med. 2013 Jan;39(1):101-8. doi: 10.1007/s00134-012-2706-x. Epub 2012 Sep 22.
Ostermann M, Chang RW Correlation between parameters at initiation of renal replacement therapy and outcome in patients with acute kidney injury. Crit Care. 2009;13(6):R175. doi: 10.1186/cc8154. Epub 2009 Nov 4.
Ronco C, Ricci Z, Bellomo R Current worldwide practice of dialysis dose prescription in acute renal failure. Curr Opin Crit Care. 2006 Dec;12(6):551-6. Review.
Schiffl H, Lang SM, Fischer R Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002 Jan 31;346(5):305-10.
Seabra VF, Balk EM, Liangos O, Sosa MA, Cendoroglo M, Jaber BL Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. Am J Kidney Dis. 2008 Aug;52(2):272-84. doi: 10.1053/j.ajkd.2008.02.371. Epub 2008 Jun 18. Review.
Vinsonneau C, Monchi M Too early initiation of renal replacement therapy may be harmful. Crit Care. 2011;15(1):112. doi: 10.1186/cc9405. Epub 2011 Jan 26.
PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy in the ICU Environment
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.